Company expects initial clinical readouts from CTIM-76 and CT-202 programs beginning in Q2 2027
Context expects cash and cash equivalents to fund operations into Q4 2027
Company plans to initiate CTIM-76 Phase 1b dose expansion trial in Q1 2027
Overview
US biopharma reported Q2 net loss widened yr/yr on higher R&D expenses
Company discontinued CT-95 to focus on CTIM-76 and CT-202 clinical programs
Cash and equivalents of $43 mln expected to fund operations into Q4 2027
Result Drivers
Higher R&D expenses - Co said increased Q2 R&D expenses were mainly due to a $6.5 mln charge for amending the BioAtla license agreement for CT-202 and higher CTIM-76 costs
Portfolio prioritization - Co discontinued CT-95 and focused resources on CTIM-76 and CT-202 clinical programs
Higher administrative costs - General and administrative expenses rose due to higher professional fees and personnel-related costs
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Context Therapeutics Inc is $5.00, about 704.1% above its August 4 closing price of $0.62
CNTX•
